I'm thinking RVX may have fallen into a bucket of dung and will come out smelling like a rose. Had this trial started around the end of May + or - it would have been at the absolute low time for new cases of COVID in North America. According to Worldometers the number of new cases in the USA this past Friday was just over 99,000, up about 3X's from its low just a few weeks before. If ABL does what we have been lead to believe it will, in a trial that starts in the next few weeks we might just have a chance of hitting this out of the ball part before the snow flies.

Having the peer reviewed write-up in the Cell, the paper from the University of Nebraska, a Break Through thearapy Designation from the FDA and a great safety record from a recently completed BoM 4400 patient year P-III trial could all be lightening rods to start a big fire under this company's share price.

It sure would be nice to see this trial start dosing in the next few of weeks.

tada